Clorox Management
Management criteria checks 4/4
Clorox's CEO is Linda Rendle, appointed in Sep 2020, has a tenure of 4.75 years. total yearly compensation is $12.69M, comprised of 9.6% salary and 90.4% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth $3.06M. The average tenure of the management team and the board of directors is 4.1 years and 5.8 years respectively.
Key information
Linda Rendle
Chief executive officer
US$12.7m
Total compensation
| CEO salary percentage | 9.63% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.1yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Clorox: Lackluster Earnings But Improving Valuation Picture (Rating Upgrade)
Jun 02Why Investors Shouldn't Be Surprised By The Clorox Company's (NYSE:CLX) P/E
Apr 24
Slowing Rates Of Return At Clorox (NYSE:CLX) Leave Little Room For Excitement
Apr 06Clorox: Reviving From Cyberattack; Initiate With 'Buy'
Mar 29Clorox: A Wonderful Business I Would Like To Own At A Lower Price
Feb 27An Intrinsic Calculation For The Clorox Company (NYSE:CLX) Suggests It's 37% Undervalued
Feb 25The Clorox Company Just Recorded A 24% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 06The Price Is Right For The Clorox Company (NYSE:CLX)
Jan 15We Think Clorox (NYSE:CLX) Can Manage Its Debt With Ease
Dec 24Return Trends At Clorox (NYSE:CLX) Aren't Appealing
Dec 02The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals
Nov 26Increases to CEO Compensation Might Be Put On Hold For Now at The Clorox Company (NYSE:CLX)
Nov 14An Intrinsic Calculation For The Clorox Company (NYSE:CLX) Suggests It's 40% Undervalued
Oct 07Why We're Not Concerned About The Clorox Company's (NYSE:CLX) Share Price
Sep 21Clorox: If You Need FMCG Player In A Portfolio - Look Elsewhere
Sep 15Clorox (NYSE:CLX) Will Pay A Larger Dividend Than Last Year At $1.22
Aug 03Here's What To Make Of Clorox's (NYSE:CLX) Decelerating Rates Of Return
Jul 29Clorox: Stellar Delivery But Valuation Compression Has Some Distance To Go
Jul 29Clorox: Questionable Growth Target Puts Me On The Sidelines
Jul 17Clorox: Improving Outlook, Good Dividend Yield And Discounted Valuation
Jun 28Colgate-Palmolive: Improved Financials To Navigate Headwinds (Rating Upgrade)
Apr 21Clorox: Relatively Overvalued And Headwinds Put Dividend At Risk
Feb 08Clorox: Not Wiped Out By Cyber Attack, Earnings And Revenue Need Cleaning Up
Jan 03Clorox: One Of The Best Household Product Portfolios
Dec 01Clorox: Undervalued But Too Many Red Flags
Oct 28Clorox: Cyberattack Compounds Existing Challenges
Oct 10Clorox: Still Struggling
Sep 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$694m |
| Dec 31 2024 | n/a | n/a | US$457m |
| Sep 30 2024 | n/a | n/a | US$357m |
| Jun 30 2024 | US$13m | US$1m | US$280m |
| Mar 31 2024 | n/a | n/a | US$240m |
| Dec 31 2023 | n/a | n/a | US$80m |
| Sep 30 2023 | n/a | n/a | US$86m |
| Jun 30 2023 | US$12m | US$1m | US$149m |
| Mar 31 2023 | n/a | n/a | US$74m |
| Dec 31 2022 | n/a | n/a | US$435m |
| Sep 30 2022 | n/a | n/a | US$405m |
| Jun 30 2022 | US$9m | US$1m | US$462m |
| Mar 31 2022 | n/a | n/a | US$458m |
| Dec 31 2021 | n/a | n/a | US$247m |
| Sep 30 2021 | n/a | n/a | US$437m |
| Jun 30 2021 | US$8m | US$1m | US$710m |
| Mar 31 2021 | n/a | n/a | US$923m |
| Dec 31 2020 | n/a | n/a | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | US$2m | US$524k | US$939m |
| Mar 31 2020 | n/a | n/a | US$870m |
| Dec 31 2019 | n/a | n/a | US$816m |
| Sep 30 2019 | n/a | n/a | US$813m |
| Jun 30 2019 | US$2m | US$436k | US$820m |
| Mar 31 2019 | n/a | n/a | US$796m |
| Dec 31 2018 | n/a | n/a | US$790m |
| Sep 30 2018 | n/a | n/a | US$841m |
| Jun 30 2018 | US$2m | US$436k | US$823m |
Compensation vs Market: Linda's total compensation ($USD12.69M) is about average for companies of similar size in the US market ($USD14.07M).
Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.
CEO
Linda Rendle (46 yo)
Ms. Linda Rendle serves as Chief Executive Officer and Director of The Clorox Company since September 14 2020 & serves as January 1, 2024. Ms. Rendle served as President of The Clorox Company from May 4, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 4.8yrs | US$12.69m | 0.019% $ 3.1m | |
| Executive VP and Chief Operating & Strategy Officer | 4.8yrs | US$4.77m | 0.044% $ 7.0m | |
| Executive VP & Chief Administrative Officer | less than a year | US$3.54m | 0.012% $ 2.0m | |
| Executive VP | 19.9yrs | US$3.45m | 0.0077% $ 1.2m | |
| Advisor | less than a year | US$4.32m | 0.043% $ 6.9m | |
| Executive VP & CFO | less than a year | no data | 0.0077% $ 1.2m | |
| VP, Chief Accounting Officer & Corporate Controller | 4.1yrs | no data | 0.0021% $ 327.6k | |
| Senior VP and Chief Information & Data Officer | 5yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Marketing Officer | 3.3yrs | no data | no data | |
| Chief Diversity Officer | 19yrs | no data | no data | |
| Executive VP and Executive Chief of Staff | 3.3yrs | US$3.56m | 0.0050% $ 792.6k |
Experienced Management: CLX's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 4.8yrs | US$12.69m | 0.019% $ 3.1m | |
| Independent Director | 9.9yrs | US$287.50k | 0.0011% $ 169.4k | |
| Independent Director | 8.8yrs | US$267.50k | 0.00049% $ 78.3k | |
| Independent Director | 9.9yrs | US$292.50k | 0.00069% $ 110.3k | |
| Director | less than a year | no data | no data | |
| Independent Director | 11.8yrs | US$282.50k | no data | |
| Lead Independent Director | 6.8yrs | US$405.00k | no data | |
| Independent Director | 8.3yrs | US$267.50k | no data | |
| Independent Director | less than a year | no data | 0.0073% $ 1.2m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.1yrs | US$267.50k | no data | |
| Independent Director | 3.1yrs | US$267.50k | no data |
Experienced Board: CLX's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/05 17:53 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Clorox Company is covered by 43 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Staszak | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Lauren Lieberman | Barclays |